acarbose
AssetSmall moleculeAlso Glucobay ODT, BAYG5421, Glucobay, BAY81-9783
Inhibits intestinal alpha-glucosidase to delay carbohydrate digestion and blunt postprandial glucose spikes
- Stage
- Approved
- Modality
- Small molecule
- Target
- Glycolysis
- Indications
- 2
- Trials
- 49
- Developers
- 1
Indications
3No named disease
Approvedaccessdata.fda.gov7 Oct 2026
Diabetes mellitus
Phase 3COMPLETEDNCT01010100clinicaltrials.gov7 Oct 2026
Type 2 diabetes
Phase 3COMPLETEDNCT00970528clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners1
- Trials49
- Evidence for its targets2
- Competitors12
- Aging relevance3
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 6 sources